This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.
The use of circulating tumor DNA (ctDNA) as a surrogate sample type for tumor tissue is an area of significant clinical interest. ctDNA has been demonstrated to mirror the solid tumor mutational landscape and has the potential for early diagnosis of cancer as well as monitoring and tracking biomarkers associated with residual disease over time.
Despite this promise, there are still open questions regarding the best way to implement liquid biopsy approaches in the clinical setting. Our panel brings together academic, clinical, and industry experts in liquid biopsy technologies who will describe the applications of this technique and discuss its benefits and shortcomings in the context of cancer care.